Ph1/2 MCLA-158 (Petosemtamab) Mono or + Pembro in CRC

Phase I/II Clinical Trial

Phase 1/2 dose escalation and cohort expansion study evaluating MCLA-158 (Petosemtamab) as single agent or in combination in advanced solid tumors (MCLA-158-CL01)

Indication: Colon Cancer, Colon Cancer, Colon Cancer, Colon Cancer, Colon Cancer, Rectal Cancer, Rectal Cancer, Rectal Cancer, Rectal Cancer, Rectal Cancer
Trial Number: 03526835
Trial Status: Call Proj Mgr

Learn more about this clinical trial.

Participating Locations